MG-132

Catalog No.S2619

MG-132 is an inhibitor of proteasome with IC50 of 100 nM in a cell-free assay, and also inhibits calpain with IC50 of 1.2 μM.

Price Stock Quantity  
USD 100 In stock
USD 50 In stock
USD 170 In stock
USD 470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

MG-132 Chemical Structure

MG-132 Chemical Structure
Molecular Weight: 475.62

Validation & Quality Control

Cited by 46 publications:

9 customer reviews :

Quality Control & MSDS

Related Compound Libraries

MG-132 is available in the following compound libraries:

Proteasome Inhibitors with Unique Features

Product Information

  • Compare Proteasome Inhibitors
    Compare Proteasome Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description MG-132 is an inhibitor of proteasome with IC50 of 100 nM in a cell-free assay, and also inhibits calpain with IC50 of 1.2 μM.
Targets Proteasome [1]
(Cell-free assay)
IC50 100 nM
In vitro MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
LPS-stimulated RAW264.7 cellsMVTGeY5kfGmxbjDBd5NigQ>?NFfZNpAzPSEQvF2=MUTEUXNQMYPJcohq[mm2czDubZRzcWNib4jp[IUheHKxZIXjeIlwdiC5aYToJGlEPTBib3[gNE4yKM7:TR?=Ml60NlQ3QTd2OU[=
HL-60M3\iSGN6fG:2b4jpZ{BCe3OjeR?=M{X2cVQxKM7:TR?=NV;tdGJ2PDhiaB?=MYfEUXNQMV7JR|UxRDFyIN88US=>M{X3WFI1Pjl5NEm2
SMMC-7721NGGxdHVEgXSxdH;4bYMhSXO|YYm=MoLUOFAh|ryPMoD6OFghcA>?NUXEfW1MTE2VTx?=NHLhT2tKSzVyPUeuNUDPxE1?Mn\3NlQ3QTd2OU[=
A-549MWPDfZRwfG:6aXOgRZN{[Xl?MoX4OFAh|ryPNILzZ4w1QCCqMW\EUXNQM130bmlEPTB:MUCg{txOMYiyOFY6PzR7Nh?=
MCF-7M17hXWN6fG:2b4jpZ{BCe3OjeR?=NVvzS3BFPDBizszNMlH5OFghcA>?MYfEUXNQMmHyTWM2OD15LkOg{txOMlXvNlQ3QTd2OU[=
SW-480MXHDfZRwfG:6aXOgRZN{[Xl?Mln4OFAh|ryPMXe0PEBpNXflSpB{TE2VTx?=M2Dt[GlEPTB;NDFOwG0>NXvTNHF2OjR4OUe0PVY>
NCI-H929NYHmPFN2S3m2b4TvfIlkKEG|c3H5NVfXeIR7OSEQvF2=MoSxO|IhcA>?NVf6TY9uTE2VTx?=NEOwZnZKSzVyPUCuNVch|ryPM4XlRVI1PjJ3MEi4
293TM3H1fGN6fG:2b4jpZ{BCe3OjeR?=NGG2T5AyOCEQvF2=NIjuRpI4OiCqM3TFN2ROW09?NUTpZZJOUUN3MEyyJO69VQ>?MYGyOFYzPTB6OB?=
293TMlzhSpVv[3Srb36gRZN{[Xl?NWHsWXBKOTBizszNMUmyOEBpMny1SG1UVw>?M2K0N21w\GW{YYTlcJkhcW6mdXPld{Bp\WG2LYPoc4NsKCB?M{PQclI1PjJ3MEi4
HeLaNVjmOG1FU2mwYYPlJGF{e2G7M3WwNlExKM7:TR?=NUf6[GpKOSCqNWT0[ZZkTE2VTx?=MU\JcoR2[2W|IGDBVnAh[2ynYY\h[4Uh[nliaX7obYJqfGmwZzDwdo9{\WG|b33lJIFkfGm4aYT5NVjWSnFvOjR|MkG4N|M>
MDA-MB-231MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUGxJO69VQ>?NGTOb4w4OiCqNHLQSW9FVVORNYKyRXk3UUN3ME2wMlE5KM7:TR?=MVyyOFE2OzJyNh?=
MCF-7MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MliwNUDPxE1?M4j4UlczKGh?MmC5SG1UVw>?MomzTWM2OD1yLkGzJO69VQ>?M3fX[VI1OTV|MkC2
MCF10AMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{DsflEh|ryPMYq3NkBpMVPEUXNQNF:xTGhKSzVyPUCuNlkh|ryPMXOyOFE2OzJyNh?=
HEK-293NUGx[oJkU2mwYYPlJGF{e2G7NGXnfIUzKGGwZDCyNEDPxE1?MoG1NkBpNYHrNHdDTE2VTx?=M4D4OGlvcGmkaYTzJGNpXC2OIHHjeIl3cXS7IIfpeIghUUN3MDDv[kA6KG6PIB?=MmTLNlM2PDB5OUC=
Calu6NYLJSHVmTnWwY4Tpc44hSXO|YYm=MXOxNEDPxE1?NUTHc2hzOThiaB?=MnrWSG1UVw>?MWLTbYdvcW[rY3HueIx6KGGlY4XteYxifGW|IH\yZZRigGmwIIDy[YN2enOxch?=NHTPPJMzOzVyNkS4Oi=>
IFN-gamma-induced RAW264.7Mn7ESpVv[3Srb36gRZN{[Xl?MmexSG1UVw>?NVzyZ4g1UW6qaXLpeJMhdmm2cnnjJI95cWSnIIDyc4R2[3Srb36ge4l1cCCLQ{WwJI9nKDBwMEe3JO69VQ>?NITMW3YzOjJ5N{K3Oy=>
IPC227FMVHDfZRwfG:6aXOgRZN{[Xl?NHTLfJcyKM7:TR?=MkOyOFghcA>?NFTwVlRFVVORMoTXTWM2OD1yLkC3O{DPxE1?MmXiNlE6OjR3Mki=
Hepa-1c1c7MUjGeY5kfGmxbjDBd5NigQ>?NFXjdFYzPSEQvF2=MVK2JIg>MnnqSG1UVw>?MYjJcoNz\WG|ZYOgUpJnOiCycn;0[YlvKGyndnXsNITJcnAzODN7MkW0OC=>
COS-7NGXJeG1EgXSxdH;4bYMhSXO|YYm=M{HMflExKM7:TR?=NYG0S4pGTE2VTx?=NVrwd2oyUUN3MEyxNEDPxE1?M2HhOVE5ODh6MEm3
HuH-7NIHpTFVEgXSxdH;4bYMhSXO|YYm=MXWxNEDPxE1?MXTEUXNQNWrxcpJ6UUN3MEyxNEDPxE1?MkXONVgxQDhyOUe=
OCI-Ly3MVHGeY5kfGmxbjDBd5NigQ>?NU\lVogxOTBizszNxsA>MmDFOEBpM1PnS2ROW09?MXrJcoR2[2W|IHj1cYFvKEmtYYDwZWJidHCqYTDzeIFjcWyrenH0bY9vKHerdHigSWM2OCCxZjCxJO69VQ>?MUmxPFAzPDFzMx?=
A2780 cDDPNVzLRmJpSXCxcITvd4l{KEG|c3H5NVLob3BzOjRiaB?=NFLJVm1FVVORMUnJcoR2[2W|IHHwc5B1d3OrczDifUBqdmirYnn0bY5oKFCWRV6g[IVoemGmYYTpc44>NF;XVWkyPzZ6NECxPC=>
LPS-stimulated RAW264.7 cellsMVTGeY5kfGmxbjDBd5NigQ>?M3XINGROW09?NYnQSW5TUW6qaXLpeJMhVkZva3HwdIFDKESQQTDibY5lcW6pM371ZlE4PDB5Mke3
PC12NHr2TGlHfW6ldHnvckBCe3OjeR?=MUGxNFAh|ryPwrC=MljsNlQhcA>?NW[2PWtITE2VTx?=MnnSTY5pcWKrdIOgOk1QUESDLTDhcoQhUDKRMj3pcoR2[2WmIHP5eI91d3irY3n0fS=>NFHsSJkyPzF3OES1OC=>
PC3MnfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH\4SVUzOCEQvF2=NGLRXmI1QCCqNYjRVVV5TE2VTx?=NEDWNVBKSzVyPUCuOkDPxE1?NFuxcZMyPjZ6NkWzOy=>
LP-1MmLTRZBweHSxc3nzJGF{e2G7NVTjUGxOOzByIH7NMoK4NlQhcA>?MYTEUXNQNEXLfVhKdmS3Y3XzJIFxd3C2b4Ppd{BjgSCrbnPy[YF{cW6pIHPs[YF3\WRiUFHSVEBt\X[nbDDhcoQhemWmdXPpcochVWOuLUGgdJJwfGWrbjDs[ZZmdA>?M2LGPFE2QTV6NUi5
ES6MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PzTGlEPTB;MD6wNVMxPiEQvF2=MljOV2FPT0WU
A101DMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXFeXpKSzVyPUCuNFMzPzlizszNNULDXYxXW0GQR1XS
OCUB-MNE\CPVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWDBZZA4UUN3ME2wMlA{PzN5IN88US=>NXj5UmVJW0GQR1XS
LB2518-MELNXvXcG1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVrTOXJOUUN3ME2wMlA{PzZizszNMn73V2FPT0WU
SH-4NXHJTXdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGPzfm9KSzVyPUCuNFQ{OSEQvF2=MXTTRW5ITVJ?
KNS-42MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3ewT2lEPTB;MD6wOFQ1OSEQvF2=MWfTRW5ITVJ?
DSH1MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjtdVhyUUN3ME2wMlA2Ojh7IN88US=>M1TL[3NCVkeHUh?=
NTERA-S-cl-D1M3zBOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1[zfmlEPTB;MD6wOVc4OiEQvF2=MXfTRW5ITVJ?
D-542MGMlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXqPYw3UUN3ME2wMlA2QTV5IN88US=>MonmV2FPT0WU
KS-1NY\4bHdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTBwME[0OVgh|ryPNX3jV|lHW0GQR1XS
BL-41MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1PCc2lEPTB;MD6wOlk1PyEQvF2=NFjxZWFUSU6JRWK=
LXF-289MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPLSlRKSzVyPUCuNFcxPjZizszNM4LYe3NCVkeHUh?=
D-247MGNGPreYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkT6TWM2OD1yLkC3NlA6KM7:TR?=NFfufG5USU6JRWK=
MMAC-SFNGf2ZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2XNcGlEPTB;MD6wO|I3QCEQvF2=NWXadoRsW0GQR1XS
CP66-MELM2DkUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTyTWM2OD1yLkC3OUDPxE1?MoK4V2FPT0WU
LB771-HNCNWXmbG1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXXndHVSUUN3ME2wMlA5ODN4IN88US=>M2nN[XNCVkeHUh?=
no-10MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVXJR|UxRTBwMEi5NFkh|ryPNWXTUlNWW0GQR1XS
A388MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWO4NIt6UUN3ME2wMlA6ODZ3IN88US=>NXLXTGxHW0GQR1XS
OPM-2MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXHJR|UxRTBwMUC0O|Qh|ryPMVfTRW5ITVJ?
OVCAR-4NETzfmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3S0NGlEPTB;MD6xNFk{QCEQvF2=NUDzNZVNW0GQR1XS
HOP-62NHXOdJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;SRpNKSzVyPUCuNVA6PDlizszNNIHpd4lUSU6JRWK=
ML-2MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnzuTWM2OD1yLkGxPFA3KM7:TR?=M3HGXXNCVkeHUh?=
UACC-257MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;VWmlEPTB;MD6xNVkzPyEQvF2=NF24PY5USU6JRWK=
NEC8M1e5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLZTWM2OD1yLkGxPVk2KM7:TR?=M4TJc3NCVkeHUh?=
ONS-76M4\xdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;QOJRKSzVyPUCuNVI6OzVizszNMn:yV2FPT0WU
KE-37NWSyVFFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIDnRlhKSzVyPUCuNVMzPzhizszNNVfhNIxmW0GQR1XS
HT-144NVrIOoZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fGNGlEPTB;MD6xN|g6PSEQvF2=MX3TRW5ITVJ?
LB2241-RCCNGfRc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWnJR|UxRTBwMUSyOFch|ryPNEnHcolUSU6JRWK=
TE-5MlzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPZfHNKSzVyPUCuNVQzPzhizszNNVTKTJZkW0GQR1XS
KINGS-1NFfucXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmHZTWM2OD1yLkG0O|kh|ryPNFXnWJRUSU6JRWK=
NCI-H69MnzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTBwMUWxOFEh|ryPMkfXV2FPT0WU
CAS-1MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTBwMUW0PFIh|ryPM{KyOHNCVkeHUh?=
D-263MGM37pZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1zaTGlEPTB;MD6xOlAxPiEQvF2=Mn\sV2FPT0WU
A253MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXfnSoNQUUN3ME2wMlE3OTJ6IN88US=>M1OxOnNCVkeHUh?=
PF-382MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NITm[ldKSzVyPUCuNVY4ODZizszNNYG3UYF2W0GQR1XS
CESSMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljrTWM2OD1yLkG3NFYh|ryPNWXldJBUW0GQR1XS
MZ2-MELNHvDOZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTBwMUe1OVkh|ryPMWXTRW5ITVJ?
HELM2LkOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2LifGlEPTB;MD6xPFUyPyEQvF2=M3PKeHNCVkeHUh?=
D-392MGNFzINlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILHbVFKSzVyPUCuNVkyOTVizszNM1T0fHNCVkeHUh?=
SK-LMS-1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIP6RVRKSzVyPUCuNVk{ODNizszNM{e1SXNCVkeHUh?=
GI-ME-NMkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1HoW2lEPTB;MD6xPVMxPiEQvF2=NXS4bWM{W0GQR1XS
LB831-BLCMk\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn7wTWM2OD1yLkG5N|Qh|ryPMnPnV2FPT0WU
DU-4475M2TpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2rqbGlEPTB;MD6xPVY2QCEQvF2=NETqW4FUSU6JRWK=
IST-SL1MmjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYiyemFYUUN3ME2wMlIxODl2IN88US=>NGXVVoFUSU6JRWK=
GAKNWm5W2ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLHfY1tUUN3ME2wMlIxPTN2IN88US=>M3XINnNCVkeHUh?=
EW-1M13JSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmPwTWM2OD1yLkKxNFQ4KM7:TR?=MUTTRW5ITVJ?
LAMA-84MkLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fXZ2lEPTB;MD6yNVg2OSEQvF2=NVHhOHlxW0GQR1XS
SK-UT-1MkLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3XlRmlEPTB;MD6yNlA1QSEQvF2=NH61fpNUSU6JRWK=
VA-ES-BJMmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXSTWM2OD1yLkKyNlU4KM7:TR?=NVuxO4w5W0GQR1XS
ACNMoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX:4[HhDUUN3ME2wMlIzPjN6IN88US=>NFvPeIxUSU6JRWK=
SK-PN-DWNHnx[25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWSySVNpUUN3ME2wMlI{OTlizszNMVzTRW5ITVJ?
HD-MY-ZMn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MonxTWM2OD1yLkKzN|A{KM7:TR?=NFnhZZdUSU6JRWK=
LB373-MEL-DMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHJVHlKSzVyPUCuNlQyQThizszNMX3TRW5ITVJ?
COLO-829NF;nXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTBwMkSyOVch|ryPNFK1fXdUSU6JRWK=
ES8MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIDWcldKSzVyPUCuNlQ4PjNizszNM2\TOXNCVkeHUh?=
RXF393M3n4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4KyXGlEPTB;MD6yOVAyPSEQvF2=M{DyXnNCVkeHUh?=
TK10NVzmTIoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTuTWM2OD1yLkK1OFM2KM7:TR?=M2HBS3NCVkeHUh?=
LOUCYNEnlVIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XHfmlEPTB;MD6yOVQ2PiEQvF2=MU\TRW5ITVJ?
MZ7-melNGrKO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXWxV245UUN3ME2wMlI3Ozd2IN88US=>MWPTRW5ITVJ?
CP67-MELMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETV[YFKSzVyPUCuNlY4OyEQvF2=M3vKS3NCVkeHUh?=
C2BBe1NUntPFhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\PVGlEPTB;MD6yO|kxPyEQvF2=MkHuV2FPT0WU
K052NVX5SoFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVHRTJZnUUN3ME2wMlI5QTlizszNMkTqV2FPT0WU
MOLT-16NHrzS5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjZc3p[UUN3ME2wMlI6PTJ2IN88US=>MX7TRW5ITVJ?
KNS-81-FDM37SOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmTMTWM2OD1yLkOwN|I{KM7:TR?=NWrKTXl5W0GQR1XS
CMKM3vZXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTBwM{GxNkDPxE1?MVvTRW5ITVJ?
LAN-6MkG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHtNpJKSzVyPUCuN|E{KM7:TR?=MVrTRW5ITVJ?
KLEMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoO1TWM2OD1yLkOxN|A3KM7:TR?=MkjqV2FPT0WU
NCCITNW\wS5JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXsSJJ1UUN3ME2wMlMyPzh|IN88US=>M3T5WXNCVkeHUh?=
HHMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1Sx[GlEPTB;MD6zNlg6PyEQvF2=M4rPS3NCVkeHUh?=
TE-8NIC2V5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTBwM{SyO|kh|ryPNHLRcGtUSU6JRWK=
GDM-1NWPKSpBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\UTWM2OD1yLkO1NVA1KM7:TR?=NHLuZWpUSU6JRWK=
NCI-H747NHv5eVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlXwTWM2OD1yLkO3NVA{KM7:TR?=NUmwb2Q4W0GQR1XS
NCI-H1092M{LNUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXpTWM2OD1yLkO4PFQ1KM7:TR?=NI\Kd|JUSU6JRWK=
8-MG-BAM{TjdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{jFWWlEPTB;MD6zPVg{PyEQvF2=M{OwTnNCVkeHUh?=
NB17MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoPjTWM2OD1yLkSyPVch|ryPNEW3PYJUSU6JRWK=
LC4-1Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTBwNEO2NFch|ryPM4njTnNCVkeHUh?=
TE-1MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIjafIxKSzVyPUCuOFUyOTlizszNNWD0dWplW0GQR1XS
KALS-1NH6zUGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGrTZZdKSzVyPUCuOFY2QDRizszNNV\0Xog3W0GQR1XS
CCRF-CEMNEHuV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPOTWM2OD1yLkS3Olc1KM7:TR?=MV\TRW5ITVJ?
OS-RC-2M2O4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\1b29KSzVyPUCuOFc6PzJizszNM3qyUnNCVkeHUh?=
A704MkSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M32wW2lEPTB;MD60PFY6OiEQvF2=NXPI[I9jW0GQR1XS
BB49-HNCMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUDzbWhnUUN3ME2wMlQ6ODl4IN88US=>M2\SNHNCVkeHUh?=
EVSA-TM37x[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7QTWM2OD1yLkS5PVEyKM7:TR?=M3rmW3NCVkeHUh?=
Mo-TNEXZfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVH5Z2cyUUN3ME2wMlUyPzZ{IN88US=>NGXzXopUSU6JRWK=
MONO-MAC-6MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTBwNUO2NVEh|ryPM2fTZnNCVkeHUh?=
BB65-RCCMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV;ofopTUUN3ME2wMlU3QDFzIN88US=>MmThV2FPT0WU
NCI-H1882NYq3[VdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnGyTWM2OD1yLkW5NFM3KM7:TR?=NH7U[IlUSU6JRWK=
TE-9MlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGTYXHNKSzVyPUCuOlExOzNizszNMXvTRW5ITVJ?
NCI-H2126Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\HSZBKSzVyPUCuOlI3PjlizszNMnfDV2FPT0WU
SF268MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mme4TWM2OD1yLk[1OlQyKM7:TR?=MYHTRW5ITVJ?
SW872MkfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\vTWM2OD1yLk[1O|I6KM7:TR?=MUjTRW5ITVJ?
LS-513M3v0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTBwNk[3OVEh|ryPNUizfnJwW0GQR1XS
NCI-H1355M2DmOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWD6UlM3UUN3ME2wMlY5PjF7IN88US=>MkPxV2FPT0WU
BL-70NWHlUIpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFnzdVFKSzVyPUCuOlk{QDhizszNNHP1cWFUSU6JRWK=
NCI-SNU-5NVTLNo43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\pdWxKSzVyPUCuOlk2PDVizszNM4jpXHNCVkeHUh?=
SNU-C2BNVroPGZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml25TWM2OD1yLkewO|M6KM7:TR?=Ml;qV2FPT0WU
GB-1NIrkcmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4jPd2lEPTB;MD63NlEzPCEQvF2=M3ywVHNCVkeHUh?=
CTB-1NY\h[2piT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HPVmlEPTB;MD63O|k2PSEQvF2=M1vxSHNCVkeHUh?=
BeckerNHXKZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nBbGlEPTB;MD63PVYzOSEQvF2=NWjtOJFNW0GQR1XS
KM12NYT4WYNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTBwOEW0OlYh|ryPNFjjcWlUSU6JRWK=
ES7M2HETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPOTWM2OD1yLki5OlUh|ryPMojLV2FPT0WU
COLO-684NGPtR4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rZN2lEPTB;MD65NFY2QCEQvF2=MUPTRW5ITVJ?
HCC2998M3vJe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7yUGw2UUN3ME2wMlk{QDV2IN88US=>NFLPT5BUSU6JRWK=
TE-10NWLwNnI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGTwTG1KSzVyPUCuPVY1OyEQvF2=NHPDdJdUSU6JRWK=
SF126NXXJR|NvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NW\RWYtRUUN3ME2wMlk5QTdzIN88US=>NWroTVVzW0GQR1XS
EKVXM1vuXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NU\IUGZqUUN3ME2xMlA{PDR{IN88US=>MlfWV2FPT0WU
KARPAS-45NWG5OWs1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzkcYVqUUN3ME2xMlA1ODF4IN88US=>MnHKV2FPT0WU
KGNNGDnUXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlqwTWM2OD1zLkC1NFQ2KM7:TR?=M3XW[HNCVkeHUh?=
ES1M2nNbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYPJR|UxRTFwMEe5NlEh|ryPMnHDV2FPT0WU
L-540M2rzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF7qOItKSzVyPUGuNVE5OzlizszNM4fafHNCVkeHUh?=
KURAMOCHINX7YXnl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkjLTWM2OD1zLkGyN|c1KM7:TR?=NHu1OYFUSU6JRWK=
LU-65MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmraTWM2OD1zLkGyO|U{KM7:TR?=MnfpV2FPT0WU
MFH-inoNXrTb45KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTFwMUe1NFEh|ryPNVjhbXdVW0GQR1XS
NCI-H23MlPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmmzTWM2OD1zLkKwOFEh|ryPMmjRV2FPT0WU
IA-LMNFXNXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvQfJhKSzVyPUGuNlQyOTZizszNM{\udHNCVkeHUh?=
PSN1M1i0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFHIfmhKSzVyPUGuNlcxOTZizszNMnrxV2FPT0WU
NCI-H719MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1zjV2lEPTB;MT6yO|QyOSEQvF2=NISydHpUSU6JRWK=
SW684MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTFwMki2OVkh|ryPMkfDV2FPT0WU
HCE-4MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH;mfJRKSzVyPUGuN|AzOjFizszNMkTYV2FPT0WU
EW-16Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHvOS5RKSzVyPUGuN|E{PDdizszNNGXBTodUSU6JRWK=
NCI-H128MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTFwM{W4NVQh|ryPNH;BfYlUSU6JRWK=
HC-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTFwM{ixO{DPxE1?M4XEN3NCVkeHUh?=
IST-MES1MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTFwNECyNFgh|ryPNXj0b5JEW0GQR1XS
RajiM2rFO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTFwNEG4OUDPxE1?NGTCRoFUSU6JRWK=
DMS-114MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHvkUlhKSzVyPUGuOFQ2OzlizszNMkTjV2FPT0WU
GI-1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFW4VZJKSzVyPUGuOFcyOzFizszNNF3Ub4pUSU6JRWK=
NCI-H2081NYfuWXk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXXZOZJrUUN3ME2xMlU2OTl4IN88US=>NGe0XI9USU6JRWK=
LC-1FM2PCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnz3TWM2OD1zLkW1NVk5KM7:TR?=M1fyZnNCVkeHUh?=
NCI-H2227M4XrW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3PJbmlEPTB;MT62NVU3OSEQvF2=Ml;5V2FPT0WU
D-502MGNU\Zdoh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYX6W454UUN3ME2xMlY4OjFzIN88US=>NUCxWIJ[W0GQR1XS
NCI-H2141NXz2RYJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4O3VmlEPTB;MT62O|MyPyEQvF2=M3jkPHNCVkeHUh?=
LS-411NMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEHGc5dKSzVyPUGuOlk5ODdizszNMYLTRW5ITVJ?
SU-DHL-1M1\SXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUmzT405UUN3ME2xMlcyOjhzIN88US=>NGDIe5lUSU6JRWK=
BB30-HNCNFjCfWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\MWmlEPTB;MT63NlY5PSEQvF2=Mn[zV2FPT0WU
TE-15M{XZU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE[0XXpKSzVyPUGuPVI{PzNizszNNV\sTXdPW0GQR1XS
JVM-3MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjrZZNqUUN3ME2xMlk{QTB2IN88US=>NUnFSXRYW0GQR1XS
IST-SL2MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTJwMEGyOVIh|ryPMnzDV2FPT0WU
EW-18MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI\1d3FKSzVyPUKuNFI{OzdizszNMVrTRW5ITVJ?
DJM-1MlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEGzfohKSzVyPUKuNFI2PTJizszNMny3V2FPT0WU
no-11M3;oNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MofjTWM2OD1{LkCzNVA1KM7:TR?=NUHPZWxyW0GQR1XS
QIMR-WILNWr6XIVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnzR3ZKSzVyPUKuNVY4PjJizszNM17pXXNCVkeHUh?=
MC-CARNVvQXmlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV\JR|UxRTJwMkK5OUDPxE1?M3jpT3NCVkeHUh?=
KM-H2MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTJwMkmwOFMh|ryPM4n2WXNCVkeHUh?=
ECC12M3S2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjSfVQyUUN3ME2yMlM4QTRizszNNGryXZFUSU6JRWK=
HCE-TNIn4WmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XoTGlEPTB;Mj60OFg5OyEQvF2=MYTTRW5ITVJ?
MFM-223Mn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoDITWM2OD1{LkWwPFcyKM7:TR?=NFzLeGFUSU6JRWK=
SW982M4nwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLhTWM2OD1{LkWxOFgh|ryPNV7PcYZHW0GQR1XS
KG-1NYPXbIgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkS4TWM2OD1{Lki4O|kyKM7:TR?=NFfKRY5USU6JRWK=
ES4NX\HUIRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlHwTWM2OD1|LkC2NVEyKM7:TR?=NYPHO2t7W0GQR1XS
SCC-3MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDDemdKSzVyPUOuNVA5PDhizszNMkH4V2FPT0WU
RH-1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPn[pdKSzVyPUOuN|g4PDhizszNM3zkW3NCVkeHUh?=
NCI-H748MmrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIXHZ3ZKSzVyPUOuOFQzPjZizszNM3rvdHNCVkeHUh?=
HCC2218NVmyVpgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVnEXZVRUUN3ME2zMlQ3QTN5IN88US=>Mnj6V2FPT0WU
MEG-01MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fxfmlEPTB;Mz61PVY5KM7:TR?=NWfPbHV6W0GQR1XS
NB12M3ftWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlr2TWM2OD1|LkW5PFg5KM7:TR?=NFy2eXFUSU6JRWK=
SNB75MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWL1NYpwUUN3ME2zMlYxOTB|IN88US=>MnS3V2FPT0WU
KMS-12-PENGHsfVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTNwNke3NlMh|ryPNWnpbXgxW0GQR1XS
SKM-1Ml7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jpPWlEPTB;Mz63NVM4PiEQvF2=M4S3UnNCVkeHUh?=
COLO-320-HSRM3nHR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPVblZ[UUN3ME2zMlc2PjN2IN88US=>NF3sXm9USU6JRWK=
NKM-1MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnfyTWM2OD1|Lke3N|c5KM7:TR?=NWi2R4dUW0GQR1XS
TE-6NH\lXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILWNJRKSzVyPUOuPVQ2PjFizszNNVPyfmdUW0GQR1XS
D-336MGNFf0WWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTRwMEGxOlYh|ryPNVywPZFTW0GQR1XS
NCI-H1650NIrQVG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXXhdIpIUUN3ME20MlE2Pzl5IN88US=>NX\DZnRSW0GQR1XS
ES3M{DpNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{jjRmlEPTB;ND6zNlgzPCEQvF2=NHrZXmxUSU6JRWK=
YTM{HhZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4[1UWlEPTB;ND6zOVQzPCEQvF2=MUPTRW5ITVJ?
ES5M4HaPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYr0b4hwUUN3ME20MlQxOjV3IN88US=>NYPKXplbW0GQR1XS
LB647-SCLCNYGy[|RtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFrwSIZKSzVyPUSuOVY{ODhizszNM3jWVnNCVkeHUh?=
HAL-01M4XxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjIWZBRUUN3ME20MlU4ODN2IN88US=>M1LiO3NCVkeHUh?=
LP-1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW[zO3JGUUN3ME20MlczOzdzIN88US=>NHTqT4VUSU6JRWK=
BC-1NV7DZ|NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlzsTWM2OD13LkCwOFQ4KM7:TR?=NF\VcINUSU6JRWK=
EB-3MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{iyWGlEPTB;NT6wN|A1OSEQvF2=MnvGV2FPT0WU
GT3TKBNGLJTYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M37ZbmlEPTB;NT6xO|Y3OiEQvF2=NHfsTXBUSU6JRWK=
NCI-H209NVPmb|J2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV\JR|UxRTVwMUmzOVIh|ryPNFzxWVBUSU6JRWK=
BT-474NIKyWXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXMTWM2OD13LkKzNVAzKM7:TR?=MnLYV2FPT0WU
RKOM{PhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M33Wd2lEPTB;NT6yN|QzOiEQvF2=NHPRVmtUSU6JRWK=
SIMANUfofFgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3rXS2lEPTB;NT6zNFc3PSEQvF2=M4nVVHNCVkeHUh?=
RLNUK3WY95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2[yVGlEPTB;NT6zO|U1OSEQvF2=Mnq5V2FPT0WU
GCIYMkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1XSRWlEPTB;NT60O|I{PiEQvF2=NVrRb4hpW0GQR1XS
Calu-6NUnQdXlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33YTWlEPTB;NT62NlIh|ryPNHnWTG1USU6JRWK=
ALL-POMne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;xTWM2OD13Lk[zO|k2KM7:TR?=M{L0N3NCVkeHUh?=
ARH-77MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEn3WWZKSzVyPUWuOlcxQDdizszNNV75bFhLW0GQR1XS
A4-FukMoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHfrbVhKSzVyPU[uNFgyOThizszNNITsOmJUSU6JRWK=
NCI-H1581NYLCWmxDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mln4TWM2OD14LkKzPFQ6KM7:TR?=NIPHepdUSU6JRWK=
HUTU-80MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mln4TWM2OD14LkO2PFk4KM7:TR?=NUTuTplkW0GQR1XS
TGWNGi2NYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MofETWM2OD14LkS1OVk{KM7:TR?=NHixU4dUSU6JRWK=
SK-N-FIM3zpNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jm[GlEPTB;Nj60OVg2PCEQvF2=NVHvNJViW0GQR1XS
U-266MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1zvPGlEPTB;Nj61NVkzPiEQvF2=MkXNV2FPT0WU
EM-2NVfnUZlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXu3OVdQUUN3ME22MlY4ODl7IN88US=>NV;3bGtCW0GQR1XS
NMC-G1NGO3SVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1XXO2lEPTB;Nj63NVg6PSEQvF2=NWTwN4Y5W0GQR1XS
KASUMI-1M333T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mmj2TWM2OD14Lki0O|g4KM7:TR?=MlT5V2FPT0WU
NALM-6NFvBV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTZwOE[3OVQh|ryPNWTOZWttW0GQR1XS
OCI-AML2MojsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PsNmlEPTB;Nz6wNFMzPiEQvF2=NWHTPIg4W0GQR1XS
SHP-77NVnKfIxET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn34TWM2OD15LkKyOFMh|ryPNYnrNXV1W0GQR1XS
NOMO-1MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYPVRpZVUUN3ME23MlI1OjV2IN88US=>M2f0R3NCVkeHUh?=
SK-N-DZNYDGPFJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mny3TWM2OD15LkexNFg6KM7:TR?=MXnTRW5ITVJ?
LB1047-RCCMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nvN2lEPTB;Nz63NlI{OSEQvF2=NEPzelVUSU6JRWK=
MZ1-PCM4fQZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVrt[JNEUUN3ME23Mlg3PTV6IN88US=>NFPkU5pUSU6JRWK=
NB10MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHzKVVRKSzVyPUeuPVk2PTZizszNMmnzV2FPT0WU
RL95-2MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRThwMUC4OFIh|ryPNYqzT|NmW0GQR1XS
OMC-1NXzRZmFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\oTlFKSzVyPUiuOVIyQTFizszNMYTTRW5ITVJ?
D-283MEDM3\VdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRThwOUG3NVkh|ryPNFT4WotUSU6JRWK=
MC116MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRThwOUe5OEDPxE1?NG[3eYNUSU6JRWK=
SJSA-1MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVLLW2tOUUN3ME25MlA6ODlzIN88US=>NH\WT4NUSU6JRWK=
JiyoyeP-2003MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M33wTGlEPTB;OT6yPVMyPyEQvF2=NULX[npyW0GQR1XS
IST-MEL1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjOTWM2OD17Lke0NVk5KM7:TR?=Mo\rV2FPT0WU
CTV-1M4LuW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LhOGlEPTB;MUCuNFk4QSEQvF2=M{nDUXNCVkeHUh?=
NH-12NVPh[lltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfjRoZXUUN3ME2xNE4zPDN|IN88US=>Mm\0V2FPT0WU
CA46M1WyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUHXU4tVUUN3ME2xNE4{PjFizszNM{H5TnNCVkeHUh?=
NCI-SNU-1M{nONGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXG3d3dPUUN3ME2xNE41QTZ7IN88US=>M1\DbnNCVkeHUh?=
SCLC-21HMmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV71T2Z5UUN3ME2xNE43PTl4IN88US=>MojjV2FPT0WU
EC-GI-10NYfFblZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTFyLkewN|Eh|ryPNGKyR5FUSU6JRWK=
SRNEjPZ|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MljITWM2OD1zMT6wNVg2KM7:TR?=MWHTRW5ITVJ?
NCI-H1648MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTFzLkC5OlUh|ryPMXPTRW5ITVJ?
TGBC1TKBMnPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mne3TWM2OD1zMT60NVAzKM7:TR?=MY\TRW5ITVJ?
EW-11NH3sbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWexXZd3UUN3ME2xNU42OTh4IN88US=>NUP6SXdtW0GQR1XS
SK-MM-2NWXmTWVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkjzTWM2OD1zMT64NFYyKM7:TR?=M1\qPXNCVkeHUh?=
NCI-H524NFjiOGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUjweIpjUUN3ME2xNU46QDJ{IN88US=>MkPtV2FPT0WU
NOS-1M1myXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlnUTWM2OD1zMj6wN|Q2KM7:TR?=MX3TRW5ITVJ?
AM-38MlmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2rSb2lEPTB;MUKuOVY{OyEQvF2=MYXTRW5ITVJ?
A498NXjTUmpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTF{LkewOlkh|ryPMWTTRW5ITVJ?
KARPAS-422NIDCfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3L2W2lEPTB;MUKuO|Q6PiEQvF2=M4H0XHNCVkeHUh?=
LU-139M1;MSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPSTWM2OD1zMj65NFI3KM7:TR?=MYHTRW5ITVJ?
COR-L88NVX2dFA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTF{LkmzPFIh|ryPNVG1UG5UW0GQR1XS
K5M3nUU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoS3TWM2OD1zMj65OFYzKM7:TR?=NEfJWZpUSU6JRWK=
NB13M1TZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDnUI1WUUN3ME2xNk46Pzh|IN88US=>NWG5elBLW0GQR1XS
MRK-nu-1MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmK0TWM2OD1zMz6xPVUh|ryPMV;TRW5ITVJ?
MHH-NB-11NVfFRlVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlvMTWM2OD1zMz6yPVAzKM7:TR?=MlT5V2FPT0WU
KU812MonIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml\iTWM2OD1zMz62NVI1KM7:TR?=M3vLe3NCVkeHUh?=
TE-12MlThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDtSIhOUUN3ME2xN{43QTl2IN88US=>MVrTRW5ITVJ?
NCI-N87MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPCTnFXUUN3ME2xN{44OzZizszNNXj6Z4pWW0GQR1XS
EB2MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFW1[WhKSzVyPUGzMlg2ODVizszNM1uxc3NCVkeHUh?=
DBM3\ucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFyzbGZKSzVyPUGzMlk5QDVizszNMX3TRW5ITVJ?
697MkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1f1V2lEPTB;MUSuOFUyOSEQvF2=MlXTV2FPT0WU
MSTO-211HM4G1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUj6[m1yUUN3ME2xOE44PDR6IN88US=>MnTPV2FPT0WU
JVM-2NFvaUWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTF2Lke3N|Uh|ryPNXTvPJlUW0GQR1XS
COLO-824MoPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV[4elZXUUN3ME2xOE44QTl2IN88US=>MXrTRW5ITVJ?
BC-3M{[1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTF3LkO5PEDPxE1?NXXmcpEzW0GQR1XS
BOKUMkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPUTWM2OD1zNT65OlA5KM7:TR?=M1L0fHNCVkeHUh?=
GOTOM2DGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7venpKSzVyPUG2Mlk3OTdizszNMkH1V2FPT0WU
HCC2157MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4fFbGlEPTB;MUeuOFc2PSEQvF2=MXnTRW5ITVJ?
LS-1034NUXqXFhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFqydYpKSzVyPUG3MlY5OThizszNNXnUbWt6W0GQR1XS
CAL-148NEC1O21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTF5Lkm3PVYh|ryPNWfaSoM6W0GQR1XS
MOLT-4NHfjdXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXrtU|dNUUN3ME2xPE45OjB6IN88US=>NIDkTIxUSU6JRWK=
DaudiMnOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTF6LkmyN|Eh|ryPMWnTRW5ITVJ?
J-RT3-T3-5NHHVSVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTF7LkSwOlYh|ryPM2rnfnNCVkeHUh?=
KMOE-2MnvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTF7Lk[0PFIh|ryPNGLzbGFUSU6JRWK=
HL-60MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF34TJdKSzVyPUKwMlE6PjVizszNNFHUZ3BUSU6JRWK=
P31-FUJMlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4LLZ2lEPTB;MkCuOFc2OyEQvF2=MYfTRW5ITVJ?
IM-9NWLnd2VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTJyLk[yNlQh|ryPMULTRW5ITVJ?
HDLM-2NUTzRnVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTJyLki4NlEh|ryPNHfYfHBUSU6JRWK=
NCI-H1304NUnrV3NWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvIOpFKSzVyPUKxMlA{OTFizszNM2TzR3NCVkeHUh?=
NCI-H345MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFi0fmdKSzVyPUKxMlA3PDNizszNM3vHdXNCVkeHUh?=
RPMI-6666NHfzNldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml;2TWM2OD1{MT6zOlAzKM7:TR?=NUPWOFZMW0GQR1XS
GR-STM2HGN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTJzLkSxO{DPxE1?M2fp[HNCVkeHUh?=
CHP-126M4PKTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2LVcGlEPTB;MkGuOlE5OSEQvF2=M13qOHNCVkeHUh?=
EHEBM2PPcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;sbXRKSzVyPUKxMlY4OzFizszNM3TxOnNCVkeHUh?=
CPC-NNYTtZZhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2\nWWlEPTB;MkSuNFIxOSEQvF2=MlX3V2FPT0WU
NB1NV\J[nc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NImxbG5KSzVyPUK0MlY6OzlizszNNFvofoZUSU6JRWK=
LS-123NUSxU2pYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1H3dGlEPTB;MkSuPVAyOiEQvF2=NEDXb|BUSU6JRWK=
ST486M4n1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWfJWFdQUUN3ME2yOU4yOTF|IN88US=>MV;TRW5ITVJ?
NCI-H1963MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfpd45SUUN3ME2yOk4xPjJ|IN88US=>NF[5[|VUSU6JRWK=
U-87-MGMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlSwTWM2OD1{Nj63OlQ1KM7:TR?=NW[1SlBFW0GQR1XS
COR-L279MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTJ4Lke5NlIh|ryPM2rIfnNCVkeHUh?=
LU-165NIPhNHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XSOGlEPTB;MkiuNFg3OSEQvF2=MWXTRW5ITVJ?
COLO-800MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTJ6LkK5OVYh|ryPM1XOT3NCVkeHUh?=
ETK-1NXfUUHZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFn1PG9KSzVyPUK4MlM1PDZizszNMU\TRW5ITVJ?
LNCaP-Clone-FGCNV3vTZU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{nGRmlEPTB;MkmuPVI5OSEQvF2=M{CxNHNCVkeHUh?=
SIG-M5MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIGxeWdKSzVyPUOwMlc6PTJizszNM4\YXnNCVkeHUh?=
NB6NILMbW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1fYd2lEPTB;M{CuPVUxOyEQvF2=MnjBV2FPT0WU
NCI-H2107M3XXOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rmeGlEPTB;M{GuNlM{QCEQvF2=NIjRZ4RUSU6JRWK=
SNU-C1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHO[5JKSzVyPUOxMlMyOjZizszNMlS0V2FPT0WU
JARNEDqepdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTNzLkO3PVkh|ryPMkXUV2FPT0WU
L-363MofiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPPd2N{UUN3ME2zNk4zOTR2IN88US=>NYfkWlVmW0GQR1XS
EW-24M3\Xb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEnub3FKSzVyPUOyMlM1PzRizszNNHjvdHFUSU6JRWK=
NB69NID5UG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MontTWM2OD1|Mz62OFU1KM7:TR?=M4DxU3NCVkeHUh?=
EW-13NVHoR2ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV\JR|UxRTN|Lki5Olkh|ryPNIHlWI1USU6JRWK=
Ramos-2G6-4C10MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGn3SXBKSzVyPUO0MlI6QTNizszNNVfJZ3h6W0GQR1XS
TE-11M{\1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkXMTWM2OD1|ND60PFIzKM7:TR?=NWHIN2VCW0GQR1XS
L-428NIXDbYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWDhc3dCUUN3ME2zOE44PTN4IN88US=>MoXaV2FPT0WU
KP-N-YNM2jKZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2rHSWlEPTB;M{SuPVA2PyEQvF2=MWrTRW5ITVJ?
CGTH-W-1NUPIRVFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTN4LkmwOFgh|ryPMon0V2FPT0WU
K-562M1zYfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVrITWRjUUN3ME2zO{4xQDZ2IN88US=>Mn\SV2FPT0WU
NCI-H1299NETVeGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{DHVWlEPTB;M{iuNVYxOyEQvF2=NVvXbotMW0GQR1XS
RCC10RGBNUnSXnlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MonzTWM2OD1|OD6yNFg{KM7:TR?=NHrLd3ZUSU6JRWK=
NCI-SNU-16MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;Bc2lEPTB;M{iuOVY2OyEQvF2=M37BTnNCVkeHUh?=
LC-2-adMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfFTWM2OD1|OT60N|M4KM7:TR?=MXHTRW5ITVJ?
MHH-PREB-1NYPSN3JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTN7LkezPFgh|ryPM3PEdHNCVkeHUh?=
NCI-H64MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjSN2dmUUN3ME20NE4xQTR6IN88US=>MmmxV2FPT0WU
LB996-RCCMn3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTRyLki3NVYh|ryPMnS3V2FPT0WU
DELM4q5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4Dn[mlEPTB;NEGuOFQxPSEQvF2=MXTTRW5ITVJ?
MLMAM{XjeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTRzLke1PVUh|ryPNI\1Z|ZUSU6JRWK=
SBC-1M3;6Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXHpSYFmUUN3ME20Nk4yQDB4IN88US=>MV7TRW5ITVJ?
MPP-89NFrHOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MknxTWM2OD12Mj61PFc2KM7:TR?=M3WxSnNCVkeHUh?=
MV-4-11Mkf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTR{LkmwOlch|ryPNWPrSJc5W0GQR1XS
EoL-1-NVP5VFZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MonoTWM2OD12ND6xOVY5KM7:TR?=NF;nToJUSU6JRWK=
CW-2M4qzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDhTWM2OD12ND64N|QzKM7:TR?=MVTTRW5ITVJ?
HTM33HN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXu1c5huUUN3ME20OU44ODB5IN88US=>MVnTRW5ITVJ?
SW954MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRTR5LkSxNlgh|ryPMoGyV2FPT0WU
A3-KAWNHq0[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXX0fVBCUUN3ME20PU45ODZzIN88US=>MojSV2FPT0WU
TC-YIKM3u5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\uTJdKSzVyPUWwMlA{PjNizszNMkTXV2FPT0WU
SW962MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1znPGlEPTB;NUSuPFM2PyEQvF2=Ml60V2FPT0WU
KP-N-RT-BM-1MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUPNNYlMUUN3ME21Ok43PjN6IN88US=>MVnTRW5ITVJ?
NCI-H1395MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2XGe2lEPTB;NUiuPFE4OiEQvF2=NEnROY9USU6JRWK=
RPMI-8402MlX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4rKbGlEPTB;NUiuPVUzPiEQvF2=MVLTRW5ITVJ?
SCHMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVXJR|UxRTZyLkm2N|gh|ryPMmPDV2FPT0WU
NCI-H2196M3LOR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTZzLkKzNUDPxE1?NILGWoRUSU6JRWK=
LOXIMVIMlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInMO5dKSzVyPU[xMlgzPjZizszNNVH1b5kzW0GQR1XS
TGBC24TKBMmq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4DhVGlEPTB;NkKuNVQ6OSEQvF2=Mm\rV2FPT0WU
SK-MEL-2Mmr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTZ|Lkm4PVIh|ryPMoTLV2FPT0WU
U-698-MM3nESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnLwTWM2OD14OD61Olg4KM7:TR?=M323VXNCVkeHUh?=
NCI-H1522M4TxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTZ7LkCwOFch|ryPMnf6V2FPT0WU
UACC-812M2rU[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPjTWM2OD14OT61NlA6KM7:TR?=M3zSenNCVkeHUh?=
MHH-CALL-2NHH2NlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTdyLkC2JO69VQ>?MX\TRW5ITVJ?
NB5MkK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\ZVWlEPTB;N{CuN|Q3QCEQvF2=NGDOU4ZUSU6JRWK=
KARPAS-299M4i0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkfrTWM2OD15MD60OFQ4KM7:TR?=Mo\qV2FPT0WU
NCI-H1694MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXDbYNKSzVyPUexMlA{OiEQvF2=MYLTRW5ITVJ?
NCI-H82MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFzDcYZKSzVyPUexMlk2ODdizszNMVHTRW5ITVJ?
SCC-15MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\jTWM2OD15Mj6zOEDPxE1?NEjOVnhUSU6JRWK=
NCI-H1436MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1r0RWlEPTB;N{KuO|Q2PiEQvF2=MlfCV2FPT0WU
ATN-1NUTnbJV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4rNcGlEPTB;N{SuOVA2KM7:TR?=NFvkUI9USU6JRWK=
RPMI-8866NFrud|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TiUGlEPTB;N{SuO|UxQSEQvF2=MkD0V2FPT0WU
HCC1599MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoTvTWM2OD15ND64O|MzKM7:TR?=MnjrV2FPT0WU
NCI-H1155MoW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTd2LkmzOlch|ryPM3Lw[nNCVkeHUh?=
DOHH-2MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MU\JR|UxRTd2Lkm1NVQh|ryPMl;lV2FPT0WU
SK-NEP-1MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlzQTWM2OD15NT6wO|U1KM7:TR?=NIi2NnNUSU6JRWK=
HCC1187MkSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MonOTWM2OD15Nz62NVIzKM7:TR?=NGCxN2dUSU6JRWK=
NCI-H322MMmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFy5TVhKSzVyPUe4MlM4ODlizszNMUDTRW5ITVJ?
NCI-H526NXW0dFhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLVbWNiUUN3ME23PE42QDd5IN88US=>MX;TRW5ITVJ?
NCI-H2171M174cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\acGlEPTB;N{muOFE{PiEQvF2=MXrTRW5ITVJ?
COLO-668NYjyWYFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3HHR2lEPTB;OEGuOVg5PCEQvF2=NYHyZ2cxW0GQR1XS
RS4-11NHLmXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{j2[mlEPTB;OEKuNlUxPSEQvF2=NGPhZ2NUSU6JRWK=
NCI-H716Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEPSVIVKSzVyPUiyMlkxPzVizszNMnjOV2FPT0WU
LU-134-ANIO3PIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUDjPXo5UUN3ME24N{4yOzVzIN88US=>NXrycmFQW0GQR1XS
RPMI-8226NYToVGM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIThSJdKSzVyPUi0MlIyODdizszNNFfsZZJUSU6JRWK=
KY821MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;IbJVKSzVyPUmxMlY2PTFizszNMX;TRW5ITVJ?
ECC4NH7UbVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfYNY1XUUN3ME25N{45OjZ7IN88US=>MoTaV2FPT0WU
EW-3M3vQcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\MTWM2OD17ND65NFgyKM7:TR?=MYfTRW5ITVJ?
NB7NXLNc45oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTl3Lke3PFYh|ryPNI[3fJBUSU6JRWK=
NCI-H720NWr3NII4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTl6LkSwOlEh|ryPM3vsXXNCVkeHUh?=
NCI-H446Mki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MknMTWM2OD17OT63OVg5KM7:TR?=NYDleJNZW0GQR1XS
NCI-H889MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M16xNGlEPTB;MUC0MlI1OiEQvF2=MYnTRW5ITVJ?
EW-22NE\tPYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Moi2TWM2OD1zME[uNVkh|ryPNXHobo01W0GQR1XS
BV-173MmSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjnfHdKSzVyPUGwPE44OjhizszNM3XhXHNCVkeHUh?=
WSU-NHLNXHyZZppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTFyOT62O|Eh|ryPMonSV2FPT0WU
MN-60M13HcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zaNGlEPTB;MUC5MlY6KM7:TR?=M2nlW3NCVkeHUh?=
DG-75Ml3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkexTWM2OD1zMUOuN|UzKM7:TR?=M1\BTHNCVkeHUh?=
DMS-79MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjY[YVKSzVyPUGxO{4{QDJizszNM{L2dnNCVkeHUh?=
SK-MEL-1Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFnVRVFKSzVyPUGxPE4xODlizszNM4\YRXNCVkeHUh?=
DMS-153NXTJVFl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTF{MT63OFUh|ryPM4HSdnNCVkeHUh?=
NCI-H510ANH3ZV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGjkT2FKSzVyPUGyO{4{OiEQvF2=MVLTRW5ITVJ?
BE-13MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXPnXnhrUUN3ME2xN|QvODR2IN88US=>NFnZXFlUSU6JRWK=
KP-N-YSMl7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjTTFNSUUN3ME2xN|kvPzN4IN88US=>MmO0V2FPT0WU
SUP-T1NIrPT2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGP6SY5KSzVyPUG0N{44ODhizszNMYDTRW5ITVJ?
EW-12Mn\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2rafWlEPTB;MUS0MlY6QSEQvF2=NHHucXRUSU6JRWK=
NB14Mm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmDqTWM2OD1zNEeuNFgzKM7:TR?=Mn[xV2FPT0WU
MDA-MB-134-VINIHXU|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVX4dGFCUUN3ME2xOFgvOjZ6IN88US=>NWHCRWx4W0GQR1XS
NCI-H1770Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnjzTWM2OD1zNU[uNlc6KM7:TR?=MWrTRW5ITVJ?
TURM120bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;kTWM2OD1zNkeuPFch|ryPM3vicnNCVkeHUh?=
NCI-H1417M2C2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFPZbGFKSzVyPUG4NE4{OzFizszNMoWzV2FPT0WU
IMR-5MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\s[WRnUUN3ME2xPFEvPTdzIN88US=>MnmxV2FPT0WU
NCI-H226NIXUNYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInYSnFKSzVyPUG4PE45PjZizszNMYnTRW5ITVJ?
NCI-H187NFHrPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUL4PWtMUUN3ME2xPVAvODZ2IN88US=>MmL1V2FPT0WU
SF539NVnTSWN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{H3TWlEPTB;MUmyMlczQCEQvF2=MWHTRW5ITVJ?
TALL-1NVf6WYQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFfVPWZKSzVyPUG5PE4{ODRizszNMVrTRW5ITVJ?
TE-441-TNUfNNpFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH;JbYlKSzVyPUG5PU44OzlizszNMVLTRW5ITVJ?
REHM1LoW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVyze|A2UUN3ME2yN|YvPjJ4IN88US=>MYjTRW5ITVJ?
MS-1MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlzTTWM2OD1{M{muNVIyKM7:TR?=MorFV2FPT0WU
THP-1NITXWYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M13CTmlEPTB;Mk[0Mlc{QCEQvF2=NITBVZBUSU6JRWK=
NCI-H1838M2DaNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTJ5MT60OVYh|ryPMX3TRW5ITVJ?
P30-OHKM2XTNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTJ6Mz64OFch|ryPNHXiNlNUSU6JRWK=
C8166MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVrJR|UxRTN2NT6zN|gh|ryPM4\XTXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

Measurement of inhibitory activities of MG-132 against 20S proteasome The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.

Cell Assay:

[3]

Cell lines KIM-2, HC11, and ES
Concentrations Dissolved in DMSO, final concentrations ~25 μM
Incubation Time 24, and 48 hours
Method

Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.

Animal Study:

[7]

Animal Models Male mdx (C57BL/10ScSn DMD mdx) mice
Formulation Dissolved in DMSO, and diluted in PBS
Dosages ~10 μg/kg/day
Administration Injection

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Tsubuki S, et al. J Biochem, 1996, 119(3), 572-576.

[2] Fiedler MA, et al. Am J Respir Cell Mol Biol, 1998, 19(2), 259-268.

view more

Chemical Information

Download MG-132 SDF
Molecular Weight (MW) 475.62
Formula

C26H41N3O5

CAS No. 133407-82-6
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 95 mg/mL (199.73 mM)
Ethanol 95 mg/mL (199.73 mM)
Water <1 mg/mL
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80, pH 4 6 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name benzyl (S)-4-methyl-1-((S)-4-methyl-1-((S)-4-methyl-1-oxopentan-2-ylamino)-1-oxopentan-2-ylamino)-1-oxopentan-2-ylcarbamate

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Proteasome Products

  • VR23

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.

  • Marimastat(BB-2516)

    Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.

  • Bortezomib (PS-341)

    Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • ONX-0914 (PR-957)

    ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • MLN9708

    MLN9708 immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • Celastrol

    Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

    Features:A potent antioxidant and anti-inflammatory drug.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Recently Viewed Items

Tags: buy MG-132 | MG-132 supplier | purchase MG-132 | MG-132 cost | MG-132 manufacturer | order MG-132 | MG-132 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us